Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,976 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Test Product Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

NCT01340625
View directory record Official record
Conditions
Bioequivalence
Interventions
Norethindrone/Ethinyl Estradiol, Ovcon® 35 Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs

NCT03127358
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
AiCure, AiCure with gamification
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

NCT03632135
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
ChemoID assay, Chemotherapy
Diagnostic Test · Drug
Lead sponsor
Cordgenics, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
13
States / cities
Los Angeles, California • New Orleans, Louisiana • Scarborough, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Phototoxicity Test (823/2016)

NCT02962856
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517, Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effect of ConcenTrace Trace Mineral Drops on Gut Health

NCT06122571
View directory record Official record
Conditions
Gut Health, Bowel Movements, Constipation, Bloating
Interventions
ConcenTrace
Other
Lead sponsor
Trace Minerals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

APOL1 Genetic Testing Program for Living Donors

NCT04910867
View directory record Official record
Conditions
Chronic Kidney Diseases, Apolipoprotein L1, Kidney Transplantation
Interventions
Components of Genetic Counseling, APOL1 genetic testing, EHR integration
Behavioral · Diagnostic Test · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

NCT04786067
View directory record Official record
Conditions
Kidney Transplant Immunosuppression
Interventions
Belatacept
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 6:13 AM EDT
Not yet recruiting Phase 2 Interventional

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336
View directory record Official record
Conditions
Lung Transplant
Interventions
Emapalumab, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 18, 2026, 6:13 AM EDT
Withdrawn Not applicable Interventional

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

NCT00675532
View directory record Official record
Conditions
Drug Dependence
Interventions
Primary Care Counseling, Cognitive-behavioral psychotherapy
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 18, 2026, 6:13 AM EDT
Completed No phase listed Observational Results available

Spy II Clinical Registry

NCT00751998
View directory record Official record
Conditions
Biliary Tract Diseases
Interventions
SpyGlass
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03237065
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Muscle Shoals, Alabama • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

NCT00401583
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
GW786034 (pazopanib), Probe drugs
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treating Comorbid Depression During Care Transitions Using Relational Agents

NCT02845102
View directory record Official record
Conditions
Chronic Illness, Chronic Pain, Depression, Comorbid Depression
Interventions
Pre-Post Feasibility
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 18, 2026, 6:13 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 2 Interventional

Effect of Tenofovir DF on Bone Metabolism in Children

NCT00088309
View directory record Official record
Conditions
HIV Infections
Interventions
Eye exam, Oral exam, CT scan, Neuropsychological testing, Electrocardiogram, Echocardiogram
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing

NCT02514798
View directory record Official record
Conditions
COPD
Interventions
Esophageal and gastric balloons, Respiratory Inductance Plethysmography (RIP) system, Sentec transcutaneous monitoring system, High-flow humidified nasal oxygen delivery system, CPAP (Positive Control)
Other · Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Results available

Biological Signatures, Probiotic Among Those With mTBI and PTSD

NCT02723344
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Post Traumatic Stress Disorder
Interventions
of Lactobacillus reuteri (L. reuteri; DSM 17938), Sunflower and medium chain triglyceride oils
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury

NCT06264752
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Level A, Level B, Passive Alert
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Altoona, Pennsylvania • Farrell, Pennsylvania • McKeesport, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 18, 2026, 6:13 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

NCT05685004
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide
Biological · Procedure · Radiation + 1 more
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

NCT00153634
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Bronchitis
Interventions
IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

NCT04883736
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Gel Microsphere, 0.1%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
973 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 18, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

NCT01182207
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 18, 2026, 6:13 AM EDT
Terminated Not applicable Interventional Results available

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

NCT02701257
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 18, 2026, 6:13 AM EDT